ArticleDiscover oncology2026
Clinical efficacy and cardiac toxicity associated with first-line dabrafenib plus trametinib in advanced BRAF V600_K601delinsE-mutated lung adenocarcinoma: a case report and literature review.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The BRAF V600_K601delinsE (c.1799_1801del) mutation is rare, with an estimated prevalence of 0.05% among all tumor types. Therapeutic options for advanced lung adenocarcinoma harboring this mutation are limited. We present a case of a patient with advanced lung adenocarcinoma carrying the BRAF V600_K601delinsE mutation who derived clinical benefit for one year from treatment with dabrafenib plus trametinib. The patient subsequently developed biventricular asynergy and a significant reduction in left ventricular ejection fraction (LVEF). This case of drug-induced cardiomyopathy is presented in the context of this known adverse reaction, which affects nearly 6% of patients receiving this combination regimen. This report contributes experience on the management of this rare genomic subtype and offers perspectives on addressing its associated adverse drug reactions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.